Mirtazapin Actavis (Mirtazapine)

Mirtazapine blocks presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and antagonizes specific serotonin receptors (5‑HT2, 5‑HT3) while also blocking H1 histamine receptors. This combined action enhances serotonergic and noradrenergic signaling, producing antidepressant and anxiolytic effects.

The appropriate dose of Mirtazapin Actavis is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions.

Safety data for mirtazapine in pregnancy and lactation are limited. The prescriber must weigh potential benefits against risks and consider alternative therapies. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To request Mirtazapin Actavis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of specific serotonin receptors and α2‑adrenergic receptors. This profile often results in stronger sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about sedation.

Mirtazapin Actavis should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Mirtazapin Actavis is taken orally, usually once daily in the evening to take advantage of its sedative effect. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include rare blood dyscrasias such as agranulocytosis, severe hepatic injury, and rare cases of Stevens‑Johnson syndrome. Additionally, patients should be monitored for emergent suicidal thoughts, especially during the early treatment phase, and for seizures in predisposed individuals.

Mirtazapin Actavis is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients, and in those currently taking monoamine oxidase inhibitors (MAOIs) unless a washout period of at least 14 days has been observed. Caution is also advised for individuals with severe hepatic impairment.